The deep mutational scanning team Octant Bio has been busy improving methods and applying them to important questions in drug discovery. They are preparing a few papers and just released a blog post here describing some of the projects; thoughts in🧵 octant.bio/blog-posts/dms…

A tour-de-force by a yuuge team UNC Pharmacology and elsewhere! A neurodevelopmental disorder mutation locks G proteins in the transitory pre-activated state pubmed.ncbi.nlm.nih.gov/39103320/

This is a big day for Exscientia! Today we announced our definitive agreement to combine with Recursion, which will bring together world-class expertise & talent to accelerate the discovery of better drugs for patients faster & at lower cost. 🧡🚀 Exscientia - I can't wait to

Did you see the big news? Want to know more? Join us for our L(earnings) Call today, 8:30am ET/6:30am MT on Thursday, August 8, where we provide a real-time livestream of the Company’s latest business developments from Co-founder and CEO Chris Gibson , Chief R&D and Chief

Here we go!

Team work makes the dream work!

Call for papers for special issue of @MolPharm_Journal celebrating the top-tier research by attendees of the 4th Transatlantic ECI GPCR Symposium for early-career scientists. More information is available here: bit.ly/4fv3yFn. #pharmacology

Recruiting a postdoctoral researcher with expertise in MD simulations of GPCRs, working with Lucie Delemotte's, my group, and our experimental collaborators. The focus of the research will be to understand the molecular mechanisms of activation. kth.se/lediga-jobb/74…

Hello Boston! After 5 amazing years in the UK at Exscientia, we boarded a plane last week and landed as future members of Recursion. Quite the change! Looking forward to the new city, and working with my new colleagues, and all you Boston biotech folk!

Big shakeup!

Register today for the 4th Transatlantic ECI GPCR Symposium on September 5-6. 2024, to promote collaboration among early-career scientists in the GPCR field. Postdocs and grad students present their research! Learn more: event.fourwaves.com/2024ecisymposi…

In a new episode of NVIDIA's #AI Podcast, Chris Gibson talks to Noah Kravitz about Recursion’s journey from an idea he began exploring at University of Utah to a leading #TechBio company with one of the largest proprietary datasets in the industry & #pharma’s fastest supercomputer. Learn

Reid Olsen (Seize the Means of Transduction) : TRUPATH is now so standard folks don't even cite the method! science.org/doi/10.1126/sc…

Following a record # of applications, our #healthcare incubator Altitude Lab in #SLC has announced 7 new #startups addressing critical needs, from improving patient outcomes & developing new therapeutic modalities to making diagnostics more accessible. altitudelab.org/articles/cohor…

Keynotes from Maria Marti Solano and Aashish Manglik, Career panel with Reid Olsen, Roshanak Irannejad, Andrew Alt, Matthew Torres & Katarzyna Ciazynska.

in-vivo reprogramming is coming… In vivo dendritic cell reprogramming for cancer immunotherapy science.org/doi/10.1126/sc…

This is our compound—now Phase 2!! “Bright Minds Biosciences initiated the BREAKTHROUGH Study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101” search.app/Y5u6U4eRkEzeYe…

In preparation for EvE's first tranche data drop (coming soon!) we're rolling out a new web site and an inaugural blog post, the first in a series addressing the question "Why map the pharmome?" evebio.org/why-map-the-ph…